Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Helix BioPharma ( (TSE:HBP) ) just unveiled an update.
Helix BioPharma Corp. announced the results of its Annual General and Special Meeting, where shareholders voted overwhelmingly in favor of all business items. Key resolutions approved include the re-election of directors, appointment of auditors, asset transactions, a financing facility, a share consolidation, and a company name change to ‘Aconara Pharma Corp.’ These decisions are poised to impact the company’s operational strategies and market positioning, potentially enhancing its financial flexibility and corporate identity.
More about Helix BioPharma
Helix BioPharma Corp. is a clinical-stage oncology company focused on developing novel therapies to treat hard-to-treat cancers. The company has a diverse pipeline of drug candidates, including its lead candidate, Tumour Defence Breaker™ L-DOS47, which is an antibody-enzyme conjugate aimed at neutralizing the microenvironment of solid tumors.
YTD Price Performance: -10.11%
Average Trading Volume: 2,055
Technical Sentiment Signal: Strong Buy
Current Market Cap: C$42.42M
See more insights into HBP stock on TipRanks’ Stock Analysis page.